The CEO of Windsor Regional Hospital is disappointed after hearing the president of Marchese Hospital Solutions speak under oath at Queens Park on Monday.

David Musyj says he is very concerned about what the company president did and did not say before the standing committee.

“They didn't offer up one possible change that they could put into place," says Musyj.

Marchese is at the centre of the diluted chemotherapy drug case. In Windsor, 290 patients received watered-down drugs, along with about 700 other patients across the province.

Marita Zaffiro, president of Marchese Hospital Solutions, testified that the company did not know how the hospitals that Marchese supplied drugs and saline in an IV bag to were distributing the drug.

“What we have learned now is that hospitals were using our products in a way that we had no idea,” says Zaffiro. “We did not know that they were using these for multi-patient use."

Musyj doesn't buy the excuse.

“I don't know any company in the world that sells a product not knowing what the end use is going to be,” says Musyj. “Be it a pencil, a vehicle, and clearly drugs being administered to patients. You have an obligation when you are providing that product to know how it's going to be used."

Musyj was disappointed that the company didn't offer any indication of strengthened policies and procedures moving forward. He says Windsor Regional is not washing its hands of any responsibility.

“Could we have weighed the medications when they came into the hospital - yes. Could we have tested every tenth bag to determine if it really had 200 ml of saline in it – yes," he says.

But the CEO says it is important changes are made at all levels.

For their part, Zaffiro says Marchese had applied to both Health Canada and the Ontario College of Pharmacists for regulatory approval, but both bodies declined to provide oversight.